Low expression of PinX1 is associated with malignant behavior in basal-like breast cancer

被引:15
作者
Feng, Yu-Zhen [1 ]
Zhang, Qing-Yan [2 ]
Fu, Mei-Ting [2 ]
Zhang, Zhen-Fei [1 ]
Wei, Min [1 ]
Zhou, Jue-Yu [1 ]
Shi, Rong [1 ]
机构
[1] Southern Med Univ, Sch Basic Med Sci, Inst Genet Engn, Guangzhou 510515, Guangdong, Peoples R China
[2] Southern Med Univ, Clin Med Coll 1, Guangzhou 510515, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
PinX1; basal-like breast cancer; malignant behavior; biomarker; molecular target; SQUAMOUS-CELL CARCINOMAS; BINDING-FACTOR PINX1; TELOMERASE ACTIVITY; PROGNOSIS; CLASSIFICATION; METASTASIS; IMMUNOHISTOCHEMISTRY; CHEMOTHERAPY; HIGHLIGHTS; SUBTYPES;
D O I
10.3892/or.2017.5696
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Human Pinx1 protein, associated with shelterin proteins, is widely revealed as a haploinsufficient tumor suppressor. Growing evidence has manifested the deregulation of PinX1 in distinct cancers. Nonetheless, the loss status of PinX1 and its diagnostic, prognostic and clinicopathological significance in Basal-like breast cancer are still unclear. In the present study, the PinX1 expression levels of breast cancer tissues were investigated by qRT-PCR and immunoblotting assays. Then immunohistochemistry (IHC) was performed to detect PinX1 expression on a tissue microarray. The optimal threshold for PinX1 positivity was determined by receiver operating characteristic (ROC) curve analysis. To clarify the probable role of PinX1 in BLBC, the PinX1 knockout and stably over-expressed MDA-MB-231 cell lines were constructed by the CRISPR-Cas9 system and gene transfection. The association of PinX1 expression with cell proliferation, migration and apoptosis of MDA-MB-231 cells were observed by CCK-8 assay, wound healing assay, Transwell assay, flow cytometric analysis and immunoblotting of the cleaved caspase-3 protein level. Our results showed that both PinX1 mRNA and protein expression were downregulated in breast cancer tissues (P<0.05). In IHC analysis, the optimal cut-off parameter for PinX1 positive expression was 62.5% (the AUC was 0.749, P<0.01). PinX1 positivity was 76.9% (10/14) in luminal subtypes, 50% (5/10) in Her2-enriched breast cancer and 27.3% (9/33) in basal-like subtypes. Besides, in 59 invasive ductal breast carcinomas, PinX1 expression was inversely related to histology grade (P<0.05) while it was positively associated with PR status (P<0.05) and ER status (P<0.05). These results indicated that low expression of PinX1 correlated with aggressive clinicopathological significance of breast cancer, especially in the basal-like subtype. Besides, we identified that overexpression of PinX1 inhibited the proliferation rates and migration ability and increased the apoptosis rates of BLBC. Our findings demonstrated that low expression of PinX1 was associated with malignant behaviors in basal-like subtype of breast cancer. PinX1 is likely a feasible biomarker and molecular target of BLBC.
引用
收藏
页码:109 / 119
页数:11
相关论文
共 39 条
[1]   Telomeres and telomerase in cancer [J].
Artandi, Steven E. ;
DePinho, Ronald A. .
CARCINOGENESIS, 2010, 31 (01) :9-18
[2]   MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model [J].
Bartholomeusz, Chandra ;
Xie, Xuemei ;
Pitner, Mary Kathryn ;
Kondo, Kimie ;
Dadbin, Ali ;
Lee, Jangsoon ;
Saso, Hitomi ;
Smith, Paul D. ;
Dalby, Kevin N. ;
Ueno, Naoto T. .
MOLECULAR CANCER THERAPEUTICS, 2015, 14 (12) :2773-2781
[3]   Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease [J].
Bianchini, Giampaolo ;
Balko, Justin M. ;
Mayer, Ingrid A. ;
Sanders, Melinda E. ;
Gianni, Luca .
NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (11) :674-690
[4]   Trastuzumab resistance induces EMT to transform HER2+ PTEN- to a triple negative breast cancer that requires unique treatment options [J].
Burnett, Joseph P. ;
Korkaya, Hasan ;
Ouzounova, Maria D. ;
Jiang, Hui ;
Conley, Sarah J. ;
Newman, Bryan W. ;
Sun, Lichao ;
Connarn, Jamie N. ;
Chen, Ching-Shih ;
Zhang, Ning ;
Wicha, Max S. ;
Sun, Duxin .
SCIENTIFIC REPORTS, 2015, 5
[5]   TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer [J].
Carey, Lisa A. ;
Rugo, Hope S. ;
Marcom, P. Kelly ;
Mayer, Erica L. ;
Esteva, Francisco J. ;
Ma, Cynthia X. ;
Liu, Minetta C. ;
Storniolo, Anna Maria ;
Rimawi, Mothaffar F. ;
Forero-Torres, Andres ;
Wolff, Antonio C. ;
Hobday, Timothy J. ;
Ivanova, Anastasia ;
Chiu, Wing-Keung ;
Ferraro, Madlyn ;
Burrows, Emily ;
Bernard, Philip S. ;
Hoadley, Katherine A. ;
Perou, Charles M. ;
Winer, Eric P. .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (21) :2615-2623
[6]   Treatment of triple negative breast cancer (TNBC): current options and future perspectives [J].
De Laurentiis, M. ;
Cianniello, D. ;
Caputo, R. ;
Stanzione, B. ;
Arpino, G. ;
Cinieri, S. ;
Lorusso, V. ;
De Placido, S. .
CANCER TREATMENT REVIEWS, 2010, 36 :S80-S86
[7]   Decreased expression of PinX1 protein predicts poor prognosis of colorectal cancer patients receiving 5-FU adjuvant chemotherapy [J].
Deng, Wenying ;
Jiao, Nanlin ;
Li, Ning ;
Wan, Xiangbin ;
Luo, Suxia ;
Zhang, Youwei .
BIOMEDICINE & PHARMACOTHERAPY, 2015, 73 :1-5
[8]   Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways [J].
Eroles, Pilar ;
Bosch, Ana ;
Alejandro Perez-Fidalgo, J. ;
Lluch, Ana .
CANCER TREATMENT REVIEWS, 2012, 38 (06) :698-707
[9]   Highlights from the 14th St Gallen International Breast Cancer Conference 2015 in Vienna: Dealing with classification, prognostication, and prediction refinement to personalize the treatment of patients with early breast cancer [J].
Esposito, Angela ;
Criscitiello, Carmen ;
Curigliano, Giuseppe .
ECANCERMEDICALSCIENCE, 2015, 9
[10]   Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 [J].
Ferlay, Jacques ;
Soerjomataram, Isabelle ;
Dikshit, Rajesh ;
Eser, Sultan ;
Mathers, Colin ;
Rebelo, Marise ;
Parkin, Donald Maxwell ;
Forman, David ;
Bray, Freddie .
INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (05) :E359-E386